Cargando…
Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer
RNA interference (RNAi) is a powerful gene-silencing platform for cancer treatment. Previously, we demonstrated that ribophorin II (RPN2), which is part of the N-oligosaccharyl transferase complex, regulates docetaxel sensitivity and tumor lethal phenotypes in breast cancer. However, the molecular f...
Autores principales: | Fujita, Yu, Yagishita, Shigehiro, Takeshita, Fumitaka, Yamamoto, Yusuke, Kuwano, Kazuyoshi, Ochiya, Takahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413657/ https://www.ncbi.nlm.nih.gov/pubmed/25595901 |
Ejemplares similares
-
RNAi Therapeutic Platforms for Lung Diseases
por: Fujita, Yu, et al.
Publicado: (2013) -
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
por: Fujita, Yu, et al.
Publicado: (2015) -
The Impact of Extracellular Vesicle-Encapsulated Circulating MicroRNAs in Lung Cancer Research
por: Fujita, Yu, et al.
Publicado: (2014) -
A novel platform to enable inhaled naked RNAi medicine for lung cancer
por: Fujita, Yu, et al.
Publicado: (2013) -
Development of Small RNA Delivery Systems for Lung Cancer Therapy
por: Fujita, Yu, et al.
Publicado: (2015)